Galecto Biotech’s Lead Molecule TD139 is Safe, & Well Tolerated, with Strong Evidence of Target Engagement and Effects on Disease Biomarkers in a Phase Ib/IIa trial in Patients with IPF
March 10, 2017
Today, Galecto Biotech AB can announce the successful completion of its phase Ib/IIa clinical trial of inhaled TD139. This novel drug, targeting Galectin-3, demonstrates ground-breaking results for patients suffering from Idiopathic Pulmonary Fibrosis (IPF), a usually fatal disease characterised by a progressive decline in lung function.
Successful trial shows unprecedented results
Galecto Biotech has successfully completed its phase Ib/IIa clinical trial of TD139, the biotech company’s new drug developed for patients suffering from Idiopathic Pulmonary Fibrosis.